Carriers of the hypertrophic cardiomyopathy MYBPC3 mutation are characterized by reduced myocardial efficiency in the absence of hypertrophy and microvascular dysfunction

European Journal of Heart Failure

Volumn 13, Issue 12, 2011, Pages 1283-1289

  Timmer, Stefan A J ^a   Germans, Tjeerd ^a   Brouwer, Wessel P ^a   Lubberink, Mark ^a   Van Der Velden, Jolanda ^a   Wilde, Arthur A M ^b   Christiaans, Imke ^b   Lammertsma, Adriaan A ^a   Knaapen, Paul ^a   Van Rossum, Albert C ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Carriers; Contractile function; Hyperaemic myocardial blood flow; Hypertrophic cardiomyopathy; Myocardial efficiency

Indexed keywords

ACETIC ACID; CARBON 11; MYOSIN BINDING PROTEIN C; OXYGEN 15;

ADULT; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENOTYPE; HEART CONTRACTION; HEART HEMODYNAMICS; HEART HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE VOLUME; HEART MUSCLE BLOOD FLOW; HEART MUSCLE OXYGEN CONSUMPTION; HEART MUSCLE PERFUSION; HEART WORK; HETEROZYGOTE; HUMAN; HYPEREMIA; HYPERTROPHIC CARDIOMYOPATHY; MALE; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

ADULT; CARDIOMYOPATHY, HYPERTROPHIC; CARRIER PROTEINS; CORONARY CIRCULATION; CORONARY VESSELS; DNA; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; MAGNETIC RESONANCE IMAGING, CINE; MALE; MICROVESSELS; MIDDLE AGED; MUTATION; MYOCARDIUM; MYOSINS; OXYGEN CONSUMPTION; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; REGIONAL BLOOD FLOW; VENTRICULAR FUNCTION, LEFT;

EID: 81855194767     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfr135     Document Type: Article

References (41)

1. Seidman JG, Seidman C. The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell 2001;104:557-567. (Pubitemid 32201950)
2. Cecchi F, Olivotto I, Gistri R, Lorenzoni R, Chiriatti G, Camici PG. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Eng J Med 2003;349:1027-1035. (Pubitemid 37087617)
3. Ishiwata S, Maruno H, Senda M, Toyama H, Nishiyama S, Seki A. Mechanical efficiency in hypertrophic cardiomyopathy assessed by positron emission tomography with carbon 11 acetate. Am Heart J 1997;133:497-503. (Pubitemid 27208926)
4. Timmer SA, Germans T, Gö tte MJ, Rüssel IK, Dijkmans PA, Lubberink M, ten Berg JM, ten Cate FJ, Lammertsma AA, Knaapen P, van Rossum AC. Determinants of myocardial energetics and efficiency in symptomatic hypertrophic cardiomyopathy. Eur J Nucl Med 2010;37:779-788.
5. Tadamura E, Tamaki N, Matsumori A, Magata Y, Yonekura Y, Nohara R, Sasayama S, Yoshibayashi M, Kamiya T, Konishi J. Myocardial metabolic changes in hypertrophic cardiomyopathy. J Nucl Med 1996;37:572-577. (Pubitemid 126618443)
6. Tadamura E, Kudoh T, Hattori N, Inubushi M, Magata Y, Konishi J, Matsumori A, Nohara R, Sasayama S, Yoshibayashi M, Tamaki N. Impairment of BMIPP uptake precedes abnormalities in oxygen and glucose metabolism in hypertrophic cardiomyopathy. J Nucl Med 1998;39:390-396. (Pubitemid 28136832)
7. Tuunanen H, Kuusisto J, Toikka J, Jääskeläinen P, Marjamäki P, Peuhkurinen K, Viljanen T, Sipola P, Stolen KQ, Hannukainen J, Nuutila P, Laakso M, Knuuti J. Myocardial perfusion, oxidative metabolism, and free fatty acid uptake in patients with hypertrophic cardiomyopathy attributable to the Asp175Asn mutation in the alpha-tropomyosin gene: a positron emission tomography study. J Nucl Cardiol 2007;14:354-365. (Pubitemid 46840295)
8. Kim IS, Izawa H, Sobue T, Ishihara H, Somura F, Nishizawa T, Nagata K, Iwase M, Yokota M. Prognostic value of mechanical efficiency in ambulatory patients with idiopathic dilated cardiomyopathy in sinus rhythm. J Am Coll Cardiol 2002;39: 1264-1268. (Pubitemid 34297864)
9. Neubauer S, Horn M, Cramer M, Harre K, Newell JB, Peters W, Pabst T, Ertl G, Hahn D, Ingwall JS, Kochsiek K. Myocardial phosphocreatineto-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 1997;96: 2190-2196. (Pubitemid 27425822)
10. Crilley JG, Boehm EA, Blair E, Rajagopalan B, Blamire AM, Styles P, McKenna WJ, Ostman-Smith I, Clarke K, Watkins H. Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J Am Coll Cardiol 2003;41:1776-1782. (Pubitemid 36584252)
11. Camici P, Chiriatti G, Lorenzoni R, Bellina RC, Gistri R, Italiani G, Parodi O, Salvadori PA, Nista N, Papi L. Coronary vasodilation is impaired in both hypertrophied and nonhypertrophied myocardium of patients with hypertrophic cardiomyopathy: a study with nitrogen-13 ammonia and positron emission tomography. J Am Coll Cardiol 1991;17:879-886.
12. Barnes E, Hall RJ, Dutka DP, Camici PG. Absolute blood flow and oxygen consumption in stunned myocardium in patients with coronary artery disease. J Am Coll Cardiol 2002;39:420-427. (Pubitemid 34117498)
13. Vanoverschelde JL, Wijns W, Depré C, Essamri B, Heyndrickx GR, Borgers M, Bol A, Melin JA. Mechanisms of chronic regional postischemic dysfunction in humans. New insights from the study of noninfarcted collateral-dependent myocardium. Circulation 1993;87:1513-1523. (Pubitemid 23133095)
14. Knaapen P, Boellaard R, Gö tte MJ, Dijkmans PA, van Campen LM, de Cock CC, Luurtsema G, Visser CA, Lammertsma AA, Visser FC. Perfusable tissue index as a potential marker of fibrosis in patients with idiopathic dilated cardiomyopathy. J Nucl Med 2004;45:1299-1304. (Pubitemid 47618526)
15. Knaapen P, Germans T, Camici PG, Rimoldi OE, Cate ten FJ, Berg ten JM, Dijkmans PA, Boellaard R, van Dockum WG, Gö tte MJ, Twisk JW, van Rossum AC, Lammertsma AA, Visser FC. Determinants of coronary microvascular dysfunction in symptomatic hypertrophic cardiomyopathy. Am J Physiol Heart Circ Physiol 2008;294:H986-H993. (Pubitemid 351253312)
16. Boellaard R, Knaapen P, Rijbroek A, Luurtsema GJ, Lammertsma AA. Evaluation of basis function and linear least squares methods for generating parametric blood flow images using 15O-water and positron emission tomography. Mol Imaging Biol 2005;7:273-285.
17. Iida H, Kanno I, Takahashi A, Miura S, Murakami M, Takahashi K, Ono Y, Shishido F, Inugami A, Tomura N. Measurement of absolute myocardial blood flow with H215O and dynamic positron-emission tomography. Strategy for quantification in relation to the partial-volume effect. Circulation 1988;78: 104-115.
18. Hermansen F, Rosen SD, Fath-Ordoubadi F, Kooner JS, Clark JC, Camici PG, Lammertsma AA. Measurement of myocardial blood flow with oxygen-15 labelled water: comparison of different administration protocols. Eur J Nucl Med 1998;25:751-759. (Pubitemid 28377039)
19. Knaapen P, Camici PG, Marques KM, Nijveldt R, Bax JJ, Westerhof N, Gö tte MJ, Jerosch-Herold M, Schelbert HR, Lammertsma AA, van Rossum AC. Coronary microvascular resistance: methods for its quantification in humans. Basic Res Cardiol 2009;104:485-498.
20. Timmer SA, Lubberink M, van Rossum AC, Lammertsma AA, Knaapen P. Reappraisal of a single-tissue compartment model for estimation of myocardial oxygen consumption by [11C]acetate PET: an alternative to conventional monoexponential curve fitting. Nucl Med Commun 2011;32:59-62.
21. Sun KT, Yeatman LA, Buxton DB, Chen K, Johnson JA, Huang SC, Kofoed KF, Weismueller S, Czernin J, Phelps ME, Schelbert HR. Simultaneous measurement of myocardial oxygen consumption and blood flow using [1-carbon-11]acetate. J Nucl Med 1998;39:272-280. (Pubitemid 28114517)
22. Germans T, Götte MJ, Nijveldt R, Spreeuwenberg MD, Beek AM, Bronzwaer JGF, Visser CA, Paulus WJ, van Rossum AC. Effects of aging on left atrioventricular coupling and left ventricular filling assessed using cardiac magnetic resonance imaging in healthy subjects. Am J Cardiol 2007;100:122-127. (Pubitemid 46961906)
23. Marcus JT, Götte MJ, DeWaal LK, Stam MR, Van der Geest RJ, Heethaar RM, van Rossum AC. The influence of through-plane motion on left ventricular volumes measured by magnetic resonance imaging: implications for image acquisition and analysis. J Cardiovasc Magn Reson 1999;1:1-6.
24. Götte MJW, Germans T, Rüssel IK, Zwanenburg JJM, Marcus JT, van Rossum AC, van Veldhuisen DJ. Myocardial strain and torsion quantified by cardiovascular magnetic resonance tissue tagging: studies in normal and impaired left ventricular function. J Am Coll Cardiol 2006;48:2002-2011. (Pubitemid 44738446)
25. Knaapen P, Götte MJ, Paulus WJ, Zwanenburg JJM, Dijkmans PA, Boellaard R, Marcus JT, Twisk JWR, Visser CA, van Rossum AC, Lammertsma AA, Visser FC. Does myocardial fibrosis hinder contractile function and perfusion in idiopathic dilated cardiomyopathy? PET and MR imaging study. Radiology 2006; 240:380-388. (Pubitemid 44098633)
26. Knaapen P, Germans T, Knuuti J, Paulus WJ, Dijkmans PA, Allaart CP, Lammertsma AA, Visser FC. Myocardial energetics and efficiency: current status of the noninvasive approach. Circulation 2007;115:918-927. (Pubitemid 46294732)
27. Maron BJ, Wolfson JK, Epstein SE, Roberts WC. Intramural ('small vessel') coronary artery disease in hypertrophic cardiomyopathy. J Am Coll Cardiol 1986;8: 545-557. (Pubitemid 16048006)
28. Timmer SA, Germans T, Götte MJ, Rüssel IK, Lubberink M, Berg ten JM, Cate ten FJ, Lammertsma AA, Knaapen P, van Rossum AC. Relation of coronary microvascular dysfunction in hypertrophic cardiomyopathy to contractile dysfunction independent from myocardial injury. Am J Cardiol 2011;107:1522-1528.
29. Choudhury L, al-Mahdawi S, French J, Oakley CM, Camici PG. An additional marker for familial hypertrophic cardiomyopathy? Coron Artery Dis 1993;4: 565-567. (Pubitemid 23274204)
30. van Dockum WG, Beek AM, Cate ten FJ, Berg ten JM, Bondarenko O, Götte MJ, Twisk JW, Hofman MB, Visser CA, van Rossum AC. Early onset and progression of left ventricular remodeling after alcohol septal ablation in hypertrophic obstructive cardiomyopathy. Circulation 2005;111:2503-2508. (Pubitemid 40696139)
31. van Dockum WG, Knaapen P, Hofman MB, Kuijer JP, Cate ten FJ, Berg ten JM, Beek AM, Twisk JW, van Rossum AC. Impact of alcohol septal ablation on left anterior descending coronary artery blood flow in hypertrophic obstructive cardiomyopathy. Int J Cardiovasc Imaging 2009;25:511-518.
32. Moore CC, Lugo-Olivieri CH, McVeigh ER, Zerhouni EA. Three dimensional systolic strain patterns in the normal human left ventricle: characterization with tagged MR imaging. Radiology 2000;214:453-466. (Pubitemid 30077702)
33. Jung WI, Sieverding L, Breuer J, Hoess T, Widmaier S, Schmidt O, Bunse M, van Erckelens F, Apitz J, Lutz O, Dietze GJ. 31P NMR spectroscopy detects metabolic abnormalities in asymptomatic patients with hypertrophic cardiomyopathy. Circulation 1998;97:2536-2542. (Pubitemid 28294500)
34. Redwood CS, Moolman-Smook JC, Watkins H. Properties of mutant contractile proteins that cause hypertrophic cardiomyopathy. Cardiovasc Res 1999;44:20-36. (Pubitemid 29431681)
35. Sweeney HL, Feng HS, Yang Z, Watkins H. Functional analyses of troponin T mutations that cause hypertrophic cardiomyopathy: insights into disease pathogenesis and troponin function. Proc Natl Acad Sci 1998;95:14406-14410. (Pubitemid 28549380)
36. Vanoverschelde JL, Wijns W, Borgers M, Heyndrickx G, Depré C, Flameng W, Melin JA. Chronic myocardial hibernation in humans. From bedside to bench. Circulation 1997;95:1961-1971. (Pubitemid 27164416)
37. Varnava AM, Elliott PM, Sharma S, McKenna WJ, Davies MJ. Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease. Heart 2000;84:476-482.
38. Ashrafian H, Redwood C, Blair E, Watkins H. Hypertrophic cardiomyopathy:a paradigm for myocardial energy depletion. Trends Genet 2003;19:263-268. (Pubitemid 36507008)
39. Abozguia K, Elliott P, McKenna W, Phan TT, Nallur-Shivu G, Ahmed I, Maher AR, Kaur K, Taylor J, Henning A, Ashrafian H, Watkins H, Frenneaux M. Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. Circulation 2010;122:1562-1569.
40. Uren NG, Camici PG, Melin JA, Bol A, de Bruyne B, Radvan J, Olivotto I, Rosen SD, Impallomeni M, Wijns W. Effect of aging on myocardial perfusion reserve. J Nucl Med 1995;36:2032-2036.
41. Germans T, Rüssel IK, Götte MJ, Spreeuwenberg MD, Doevendans PA, Pinto YM, van der Geest RJ, van der Velden J, Wilde AA, van Rossum AC. Hypertrophic cardiomyopathy mutations affect myocardial function in carriers with normal wall thickness? Assessment with cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2010;12:13.